Evidence map›Paper›PMID 41559515›Full record

ArticleMetabolomics : Official journal of the Metabolomic Society2026

Diagnostic and therapeutic potential of serum fatty acids in hyperlipidemia: evidence from three cohorts of patients with coronary atherosclerotic heart disease.

Haiyan Cao, Furong Zhao, Hongbo Liu, Jingchun Huang, Shuang Wang, Haiwen Liu, Fang Liu, Ying Li, Yuanye Xia, Dongming Wang and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Metabolomics : Official journal of the Metabolomic Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Haiyan Cao *Department of Clinical Laboratory, the Fourth Affiliated Hospital of Harbin Medical University, 766 Xiangan North Street, Songbei Street, Songbei District, Harbin, 150001, Heilongjiang, China.
Furong Zhao *Liaoning Provincial Key Laboratory of Clinical Oncology Metabonomics, First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.
Hongbo LiuDepartment of Clinical Laboratory, the Fourth Affiliated Hospital of Harbin Medical University, 766 Xiangan North Street, Songbei Street, Songbei District, Harbin, 150001, Heilongjiang, China.
Jingchun HuangDepartment of Clinical Laboratory, the Fourth Affiliated Hospital of Harbin Medical University, 766 Xiangan North Street, Songbei Street, Songbei District, Harbin, 150001, Heilongjiang, China.
Shuang WangClinical Research Department, Dalian Boyuan Medical Technology Co., LTD, Dalian, China.
Haiwen LiuLiaoning Provincial Key Laboratory of Clinical Oncology Metabonomics, First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.
Fang LiuDepartment of Clinical Laboratory, the Fourth Affiliated Hospital of Harbin Medical University, 766 Xiangan North Street, Songbei Street, Songbei District, Harbin, 150001, Heilongjiang, China.
Ying LiClinical Research Department, Dalian Boyuan Medical Technology Co., LTD, Dalian, China.
Yuanye XiaDepartment of Clinical Laboratory, the Fourth Affiliated Hospital of Harbin Medical University, 766 Xiangan North Street, Songbei Street, Songbei District, Harbin, 150001, Heilongjiang, China.
Dongming WangDepartment of Clinical Laboratory, the Fourth Affiliated Hospital of Harbin Medical University, 766 Xiangan North Street, Songbei Street, Songbei District, Harbin, 150001, Heilongjiang, China.
Bin LiDepartment of Clinical Laboratory, the Fourth Affiliated Hospital of Harbin Medical University, 766 Xiangan North Street, Songbei Street, Songbei District, Harbin, 150001, Heilongjiang, China.
Ye ZhengDepartment of Clinical Laboratory, the Fourth Affiliated Hospital of Harbin Medical University, 766 Xiangan North Street, Songbei Street, Songbei District, Harbin, 150001, Heilongjiang, China.
Yu LiuDepartment of Clinical Laboratory, the Fourth Affiliated Hospital of Harbin Medical University, 766 Xiangan North Street, Songbei Street, Songbei District, Harbin, 150001, Heilongjiang, China. ranifall1982@163.com.

Funding

National Natural Science Foundation of China No.82272389Wu Jieping Science Foundation No. 320. 6750. 20220618
6 · The paper itself

Abstract

backgroundHyperlipidemia is a major risk factor for coronary atherosclerotic heart disease (CAHD). However, conventional lipid profiling fails to fully reflect the complexity of lipid metabolism. Furthermore, while lipidomics has identified numerous complex lipids as biomarkers, the role of their fundamental constituents-serum fatty acids-remains less explored in CAHD. In this study, we performed detailed profiling of serum fatty acid species to explore their utility in improving the identification and management of lipid disorders specifically within the CAHD population, an approach whose clinical value in this context remains underexplored.

methodsThe study analyzed serum fatty acid profiles in three CAHD cohorts: a training cohort (n = 432) and two external validation cohorts (n = 1302 and n = 1458). Serum samples were collected during initial and subsequent hospitalizations. A total of 39 fatty acids were quantified using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Multivariate analyses were conducted to identify fatty acids with diagnostic relevance, followed by model development and external validation.

resultsIn CAHD patients, several fatty acids were significantly correlated with total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (Apo B). Among these, esterified linoleic acid demonstrated a strong correlation with lipid biomarker (r > 0.69, p < 0.001). Logistic regression analysis identified esterified oleic acid (OR = 37.80, p < 0.001) and linoleic acid (OR = 10.74, p < 0.001) as independent significant risk factors for hyperlipidemia. The combined model incorporating these fatty acids demonstrated an AUC exceeding 0.94 (95% CI: 0.93-0.95) in both training and validation cohorts, with sensitivity and specificity exceeding 85.6% and 81.0%, respectively. Notably, during statin therapy, linoleic acid decreased significantly and was associated with favorable lipid-lowering effects, comparable to the rate of change in TC, with no significant difference.

conclusionsEsterified linoleic acid (C18:2 n6) and oleic acid (C18:1 n9) were identified as key serum biomarkers for hyperlipidemia in CAHD patients, and their combination yielded the best diagnostic performance. Moreover, C18:2 n6 decreased during statin therapy and may serve as a useful marker for monitoring treatment response.

Indexed as

Coronary Artery DiseaseFatty AcidsHyperlipidemiasAgedBiomarkersChromatography, LiquidCohort StudiesFemaleHumansMaleMiddle AgedTandem Mass SpectrometryBiomarkersFatty AcidsCoronary atherosclerotic heart disease (CAHD)Esterified and non-esterified fatty acidsHyperlipidemiaLC–MS/MSLinoleic acidOleic acid

Identifiers

PMID41559515

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.